Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Non invasive Cell Based Liquid Biopsy Platform for Bladder Cancer

Funder: European Commission

Funding period
EUR 3.7 M
USD 4.3 M
Funding amount
Abstract
OneRNA4Bladder aims to save lives and reduce cost of care for bladder cancer treatment – the most expensive type of cancer to treat due to expensive diagnostic procedures and ineffective drugs leading to a recurrence rate of 70%. Implementing the OneRNA4Bladder system for bladder cancer recurrence detection could cut the cost of managing bladder cancer in half, resulting in savings of more than €800 million/year in Europe.

The key project technology is a patented Urine Cancer Cell Filtration Device (UCCFD) that enables the selection of tumor cells from a simple urine sample. The UCCFD was developed and validated in a small prospective clinical study by the Danish Cancer Society and in-licensed by Genomic Expression Aps (GEx). In OneRNA4Bladder, GEx aims at the clinical validation of the UCCFD – in combination with DNA biomarkers – for the detection of bladder cancer recurrence. Furthermore, the UCCFD can – in combination with GEx’s proprietary OneRNA™ platform, which links RNA's to drugs that can provide a more effective treatment – be applied as a liquid biopsy platform to monitor the disease response to treatment without invasive biopsies or cystoscopies. In OneRNA4Bladder, we will also clinically validate the UCCFD technology together with OneRNA™ as a liquid biopsy platform.

OneRNA4Bladder is an opportunity for GEx to enter the world-wide bladder cancer diagnostic market. The accomplishment of the project objectives will represent a significant business opportunity for the SME, with expected sales of over €165 million within 5 years of launch.
Similar projects All >
Sorted by: Start Date
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 299,860
2017 - 2019
Project list item
Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers

Congressionally Directed Medical Research Programs to Youngjae You

USD 592,000
2015 - 2016
Project list item
Development of the UroMark assay. A non-invasive test for the detection of bladder cancer in urinary sediment cells

Medical Research Council to John Kelly, Martin Anyim, Norman R Williams, Chris Brew-Graves, Stephan Beck, Andrew Feber

USD 2,167,155
2015 - 2019
Project list item
bLadder cAncer URine cEll aNalysis

European Commission

USD 3,534,487
2015 - 2018

System

Categories
  • FOR (ANZSRC)

    0903 Biomedical Engineering

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Prevention

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science